| Status: Excluded due to NICE appraisal | |
Product meets AWMSG exclusion criteria due to NICE appraisal TA1048: Lisocabtagene maraleucel for treating relapsed or refractory large B-cell lymphoma after first-line chemoimmunotherapy when a stem cell transplant is suitable |
|
Medicine details |
|
| Medicine name | lisocabtagene maraleucel (Breyanzi®) |
| Formulation | 1.1-70 × 10^6 cells/mL / 1.1-70 × 10^6 cells/mL dispersion for infusion |
| Reference number | 4591 |
| Indication | Treatment of relapsed or refractory large B-cell lymphomas after first-line chemotherapy when a stem cell transplant is suitable |
| Company | Bristol-Myers Squibb Pharmaceuticals Ltd |
| BNF chapter | Malignant disease & immunosuppression |
| Submission type | N/A |
| Status | Excluded due to NICE appraisal |
| Date of issue | 30/01/2025 |
| NICE guidance | |